Biophytis S.A. participated in NVIDIA's GTC conference from March 16 to 19, 2026, in collaboration with LynxKite Technologies and Nebius to showcase AI-driven drug discovery for longevity. The company held investor meetings, demonstrated its MAS receptor and BIO101 candidate at the Nebius booth, and highlighted its expertise in aging biology.
Key takeaways
Biophytis participated in NVIDIA GTC 2026 held March 16-19, 2026 with over 25,000 attendees
Collaboration with LynxKite Technologies and Nebius on AI-driven computational approaches for drug discovery in longevity
Demonstrated MAS receptor and lead candidate BIO101 at Nebius booth using GPU computing
BIO101 in development for sarcopenia (Phase 3 ready) and obesity (Phase 2 ready)
Held meetings with investors and industrial partners to explore longevity collaborations